AI Article Synopsis

  • Molecular-based techniques like the FilmArray BCID panel can speed up the diagnosis of infectious diseases, leading to improved patient outcomes.
  • The study compared the FilmArray panel results from various clinical specimens with traditional culture methods, finding a 75% agreement and highlighting differences in sensitivity across sample types.
  • While the FilmArray BCID panel shows promising results, particularly for abscess samples, further cost-benefit analysis is needed before it can be widely integrated into diagnostic protocols.

Article Abstract

Molecular-based techniques reduce the delay in diagnosing infectious diseases and therefore contribute to better patient outcomes. We assessed the FilmArray blood culture identification (BCID) panel (Biofire Diagnostics/bioMérieux) directly on clinical specimens other than blood: cerebrospinal, joint, pleural and ascitic fluids, bronchoscopy samples and abscesses. We compared the results from 88 samples obtained by culture-based techniques. The percentage of agreement between the two methods was 75 % with a Cohen κ value of 0.51. Global sensitivity and specificity using the FilmArray BCID panel were 71 and 97 %, respectively. Sensitivity was poorer in samples with a low bacterial load, such as ascitic and pleural fluids (25 %), whereas the sensitivity for abscess samples was high (89 %). These findings suggest that the FilmArray BCID panel could be useful to perform microbiological diagnosis directly from samples other than positive blood cultures, as it offers acceptable sensitivity and moderate agreement with conventional microbiological methods. Nevertheless, cost-benefit studies should be performed before introducing this method into algorithms for microbiological diagnostics.

Download full-text PDF

Source
http://dx.doi.org/10.1099/jmm.0.000180DOI Listing

Publication Analysis

Top Keywords

bcid panel
12
filmarray blood
8
blood culture
8
culture identification
8
infectious diseases
8
filmarray bcid
8
samples
6
blood
5
efficacy filmarray
4
panel
4

Similar Publications

Article Synopsis
  • * The study analyzed a total of 174 monomicrobial blood cultures, finding that the majority of targeted Gram-negative and all Gram-positive organisms were successfully identified, demonstrating high sensitivity and specificity for detecting specific resistance mechanisms.
  • * Overall, the QIAstat-Dx kits showed strong correlation in both pathogen identification and predicting β-lactam resistance, marking significant progress in rapid diagnostic methods for blood infections.
View Article and Find Full Text PDF

Unlabelled: Rapid identification of methicillin-susceptible (MSSA) bacteremia may optimize antibiotic use and clinical outcomes. The study objective was to assess the impact of the BioFire® blood culture identification (BCID) polymerase chain reaction (PCR) panel on antibiotic use and clinical outcomes in patients with MSSA bacteremia. This was a retrospective chart review of adult inpatients with MSSA bacteremia during the pre-PCR (June 2018-December 2019) and post-PCR (June 2020-December 2021) implementation periods.

View Article and Find Full Text PDF

Unlabelled: The QIAstat-Dx BCID Panels (RUO) ("QIAstat," QIAGEN, Hilden, Germany) for identification of 13 Gram-negative bacteria and 18 antimicrobial resistance (AMR) gene groups was evaluated. The study was conducted in two phases; in phase 1, analytical performance was evaluated against 154 challenge isolates against whole genome sequencing data. In this phase, sensitivity and specificity of organism identification calls were 153/154 (99.

View Article and Find Full Text PDF

Objectives: To outline the procedural implementation and optimization of rapid diagnostic test (RDT) results for bloodstream infections (BSIs) and to evaluate the combination of RDTs with real-time antimicrobial stewardship team (AST) support plus clinical surveillance platform (CSP) software on time to appropriate therapy in BSIs at a single health system.

Methods: Blood culture reporting and communication were reported for four time periods: (i) a pre-BCID [BioFire® FilmArray® Blood Culture Identification (BCID) Panel] implementation period that consisted of literature review and blood culture notification procedure revision; (ii) a BCID implementation period that consisted of BCID implementation, real-time results notification via CSP, and creation of a treatment algorithm; (iii) a post-BCID implementation period; and (iv) a BCID2 implementation period. Time to appropriate therapy metrics was reported for the BCID2 time period.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the impact of the BioFire® FilmArray® blood culture identification panels on the time to optimal therapy (TTOT) for bacteremia caused by specific organisms at two community hospitals.
  • - Results showed no significant differences in overall TTOT between groups before and after implementing the BCID panels, but BCID2 saw more timely therapy adjustments and effective carbapenem use for gram-negative bacteria.
  • - There was also a notable decrease in the length of vancomycin treatment for gram-positive bacteria after BCID2 was implemented, indicating improved antimicrobial prescribing practices.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!